Prep for Journal Club Introduction - Multi-Omics Integration Series
2026-01-29
Definition: Integration of multiple high-throughput molecular profiling technologies, each measuring a different layer of cellular regulation.
Core Omics Types:
Genomics: DNA sequence and variation
Epigenomics: DNA modifications and chromatin structure
Transcriptomics: RNA expression levels
Proteomics: Protein abundance and modifications
Metabolomics: Small molecule metabolites
Extended Definition (2026): Also includes imaging data (radiomics), flow cytometry (CyTOF), spatial information, and clinical/phenotypic co-variates.
1. Sample-Focused Analysis: Classify and understand biological samples
2. Feature-Focused Analysis: Identify relationships between molecular features across layers
Objective: Improve classification and stratification of biological samples
Unsupervised Approaches:
Integrative clustering to discover sample groupings
Latent factor models to extract underlying variation patterns
Example: Identifying cancer subtypes from multi-omics profiles
Supervised Approaches:
Predict clinical outcomes or other response variables
Identify biomarkers associated with outcomes
Example: Precision medicine treatment selection
Key Advantage: Captures complex relationships across data types that single-omics approaches miss
Objective: Understand regulatory mechanisms across molecular layers
Approaches:
Identify relationships between specific feature pairs (e.g., methylation-expression)
Build multilayered regulatory networks
Infer how regulation flows from DNA → RNA → Protein → Metabolite
Examples from Literature:
Gene expression and methylation studies
Transcriptome-wide association studies (TWAS): linking genetic variants to expression
Metabolic flux balance analysis with transcriptomics integration
Ultimate Goal: Systems biology models that explain molecular mechanisms of health and disease
Historical Approach: Analyze each omics independently, then combine results
Easy to implement
Misses cross-layer interactions
Less statistical power
Modern Integrative Approaches:
Meta-analysis methods: Combine statistical evidence across layers
Bayesian methods: Model relationships with prior knowledge
Latent factor analysis: Extract shared variation patterns (e.g., MOFA)
Machine/deep learning: Pattern recognition across modalities
Regression-based: Model one layer as function of others (e.g., mixOmics)
Hybrid Example: mixOmics performs outcome prediction AND builds co-regulation networks
Methodological Questions:
How do we move from correlation to causation in multi-omics networks?
How should temporal dynamics be integrated into multi-omics models?
What is the optimal experimental design for different research questions?
Biological Questions:
Which regulatory relationships are consistent across contexts vs. condition-specific?
How do post-translational modifications fit into multi-omics regulatory models?
Can we build predictive models of cellular state from multi-omics data?
Practical Questions:
What is the minimum viable multi-omics experiment for a given question?
How do we validate multi-omics biomarkers for clinical use?
When does multi-omics provide value beyond well-executed single-omics?
Different technologies have vastly different properties:
Signal-to-noise ratios vary widely
Number of detected features differs by orders of magnitude
Coverage of molecular space is incomplete and biased
Statistical power varies substantially across platforms
Critical Implication: Lack of detected association may reflect technical limitations rather than biological absence
Four Key Challenge Areas:
1. Missing Values: Incomplete sample coverage, platform limitations, technical failures
2. Interpretability: Difficulty building queryable systems models from complex multi-omics data
3. Data Sharing: Distributed storage, inconsistent annotation, lack of standards
4. Computational Performance: Scalability, resource requirements, need for cloud infrastructure
Why Single-Cell Multi-Omics Matters:
Accounts for cell-type heterogeneity (crucial for tumors, brain, immune system)
Enables cell-type-specific regulatory models
Links molecular states to cellular phenotypes
Current Technologies:
Parallel methods: measure multiple omics from the same cell (e.g., 10x Multiome, CITE-seq)
Non-parallel methods: integrate datasets across modalities using computational matching
New Dimensions Available at Single-Cell Level:
CRISPR perturbations
Spatial localization
Lineage tracing
Trajectory inference
Technical Challenges:
Extreme sparsity, especially in scATAC-seq
Limited protein capture (targeted panels only)
Low read coverage per cell
Technology-specific noise and bias
Analytical Challenges:
Cell-type matching across non-parallel datasets
Handling dropout and missing values
Computational scaling (millions of cells)
Building interpretable models from sparse single-cell data
Major Update Since 2021: Spatial omics revolution preserves tissue architecture and cell-cell interactions
Emerging Consensus Areas:
Cloud computing is becoming standard for large-scale analysis
Latent factor models are widely adopted for integration
Single-cell multi-omics is replacing bulk approaches
Spatial information is increasingly recognized as essential
Persistent Debates:
Supervised vs. unsupervised approaches for biomarker discovery
When to use complex integration vs. simpler separate analyses
How to validate multi-omics findings across cohorts
Path from research findings to clinical implementation
Technology Trends (Post-2021):
Foundation models and large language models for biology
Improved proteomics coverage (Olink, SomaScan)
Multi-omics single-cell kits becoming commercially available
Knowledge graphs for systems biology integration
For Cancer Biology:
Which cancer questions truly require multi-omics approaches?
How do we integrate TCGA data (good genomics/transcriptomics) with limited proteomics/metabolomics?
Can multi-omics predict therapy resistance better than genomics alone?
For Methods Development:
How do we assess whether integration methods add value vs. single-omics?
What validation strategies establish confidence in multi-omics biomarkers?
How should we handle the tradeoff between model complexity and interpretability?
For Clinical Translation:
What is the path from multi-omics biomarker discovery to FDA approval?
How do we design cost-effective clinical multi-omics assays?
Which omics provide the most value for specific clinical questions?
Proposed Session Topics:
Session 1 (Today): Definitions, goals, and landscape overview
Session 2: Statistical methods deep-dive (latent factors, Bayesian approaches, regularization)
Session 3: Cancer applications (TCGA multi-omics, precision oncology case studies)
Session 4: Single-cell multi-omics technologies and analysis methods
Session 5: Spatial multi-omics and tumor microenvironment
Session 6: Clinical translation challenges and regulatory considerations
Session 7: Practical analysis demonstration OR AI/foundation models in multi-omics
For Each Session: Balance between methods understanding and biological interpretation
Original Paper:
Tarazona, S., Arzalluz-Luque, A. & Conesa, A. Undisclosed, unmet and neglected challenges in multi-omics studies. Nat Comput Sci 1, 395-402 (2021).
Suggested Additional Reading for Series:
Spatial omics reviews (2023-2024)
Single-cell multi-omics methods reviews
TCGA PanCancer Atlas papers
Clinical multi-omics biomarker validation studies
Key Tools to Explore:
mixOmics (R package for integration and visualization)
MOFA/MOFA+ (latent factor models in Python/R)
Seurat (single-cell integration in R)
Scanpy (Python single-cell ecosystem)